Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

Figures

• 

  Figure 1.. Validation study summary schema. Hgb, hemoglobin; LN, lymph node; β2M, β2-microglobulin.

• 

  Figure 2.. PFS and OS by risk category using the PET-based score compared with FLIPI-2 in the E2408 cohort. (A) PFS using the PET-based score. The KM Ests are shown with 2-year PFS of 70% in the high-risk group (score, 4-6), 87% in the intermediate-risk group (score, 2-3), and 91% in the low-risk group (score, 0-1). (B) PFS using FLIPI-2. The KM Ests are shown with 2-year PFS of 79% in the high-risk group (score, 3-5), 85% in the intermediate-risk group (score, 1-2), and 100% in the low-risk group (score, 0). (C) OS using the PET-based score. The KM Ests are shown with 2-year OS of 82% in the high-risk group, 93% in the intermediate-risk group, and 97% in the low-risk group. (D) OS using FLIPI-2. The KM Ests are shown with 2-year OS of 87% in the high-risk group, 93% in the intermediate-risk group, and 100% in the low-risk group. CI, confidence interval; Est, estimate; KM, Kaplan-Meier; NE, not estimable.

• 

  Figure 3.. PFS and OS by risk category using the PET-based score compared to FLIPI-2 in the Mayo/Iowa SPORE MER cohort. (A) PFS using the PET-based score. The KM Ests are shown with 2-year PFS of 49% in the high-risk group (score, 4-6), 69% in the intermediate-risk group (score, 2-3), and 79% in the low-risk group (score, 0-1). (B) PFS using FLIPI-2. The KM Ests are shown with 2-year PFS of 59% in the high-risk group (score, 3-5), 75% in the intermediate-risk group (score, 1-2), and 87% in the low-risk group (score, 0). (C) OS using the PET-based score. The KM Ests are shown with 2-year OS of 80% in the high-risk group, 91% in the intermediate-risk group, and 97% in the low-risk group. (D) OS using FLIPI-2. The KM Ests are shown with 2-year OS of 85% in the high-risk group, 95% in the intermediate-risk group, and 99% in the low-risk group. CI, confidence interval; NE, not estimable.

• 

  Figure 4.. POD24 using the PET-based score compared with FLIPI-2. (A) POD24 using the PET-based score in the E2408 cohort. The KM Ests are shown with rate of POD24 of 30% in the high-risk group (score, 4-6), 13% in the intermediate-risk group (score, 2-3), and 9% in the low-risk group (score, 0-1). (B) POD24 using FLIPI-2 in the E2408 cohort. The KM Ests are shown with rate of POD24 of 21% in the high-risk group (score, 3-5), 15% in the intermediate-risk group (score, 1-2), and 0% in the low-risk group (score, 0). (C) POD24 using the PET-based score in the Mayo/Iowa SPORE MER cohort. The KM Ests are shown with rate of POD24 of 49% in the high-risk group, 23% in the intermediate-risk group, and 13% in the low-risk group. (D) POD24 using FLIPI-2 in the Mayo/Iowa SPORE MER cohort. The KM Ests are shown with rate of POD24 of 35% in the high-risk group, 17% in the intermediate-risk group, and 4% in the low-risk group. CI, confidence interval; NE, not estimable.